帕金森病医药联合门诊药学服务路径的建立与实践

Establishment and practice of pharmaceutical service pathway in Parkinson’s disease combined medical clinic

目的建立帕金森病医药联合门诊药学服务路径,规范药学门诊服务工作。方法根据现状调查结果,建立帕金森病医药联合门诊药学服务路径,包括用药方案评估、提供用药咨询及个体化宣教。对2022年7~12月就诊于帕金森病医药联合门诊的50例PD患者按该药学服务路径开展工作,并评价药学服务成效。结果按该药学服务路径工作6个月后,50例PD患者UPDRS综合评分Ⅲ、Ⅳ部分均低于服务前,且差异有统计学意义(P<0.05)。服务前后依从性Morisky评分为0分的(依从性好)从7例增加至25例,评分为3~4分(依从性差)的从13例减少至2例。此外,随访期间,未见严重不良反应。结论建立帕金森病医药联合门诊药学服务路径,有助于提高患者服药依从性,改善临床疗效,减少不良反应发生,并促进药学门诊服务工作规范化。

Objective To establish pharmaceutical service pathway in combined medical clinic for Parkinson’s disease patients and ensure the normalization of pharmaceutical services.Methods Based on the current investigation results,the working mode of pharmaceutical services for Parkinson’s disease patients was established,including medication plan evaluation,medication consultation,and personalized education.And 50 PD patients who visited our combined medical clinic from July to December 2022 were carried out according to the pharmaceutical service pathway,and the effectiveness was evaluated.Results After 6 months of service using this pathway,the UPDRS comprehensive scores of 50 PD patients in partsⅢandⅣwere lower than those before service,and the difference was statistically significant(P<0.05).The Morisky score of 0(good compliance)increased from 7 to 25 people before and after service,and the score of 3~4(poor compliance)decreased from 13 to 2 people.In addition,no serious adverse reactions were observed during the follow-up period.Conclusion Establishing pharmaceutical service pathway in combined medical clinic for Parkinson’s disease patients can increase medication compliance,improve clinical efficacy,reduce adverse reactions,and promote standardization of pharmaceutical outpatient service work.